AUB ScholarWorks

Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab

Show simple item record

dc.contributor.author Daher M.
dc.contributor.author Lacouture M.E.
dc.contributor.author Rathkopf D.
dc.contributor.author Maki R.G.
dc.contributor.author Keohan M.L.
dc.contributor.author Gansukh B.
dc.contributor.author Chen H.
dc.contributor.author Abou-Alfa G.K.
dc.contributor.editor
dc.date 2011
dc.date.accessioned 2017-10-05T15:41:27Z
dc.date.available 2017-10-05T15:41:27Z
dc.date.issued 2011
dc.identifier 10.1200/JCO.2010.34.5116
dc.identifier.isbn
dc.identifier.issn
dc.identifier.uri http://hdl.handle.net/10938/17976
dc.description.abstract [No abstract available]
dc.format.extent
dc.language English
dc.publisher ALEXANDRIA
dc.relation.ispartof Publication Name: Journal of Clinical Oncology; Publication Year: 2011; Volume: 29; no. 21;
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab
dc.type Article
dc.contributor.affiliation Daher, M., American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Lacouture, M.E., Memorial Sloan-Kettering Cancer Center, New York, NY, United States
dc.contributor.affiliation Rathkopf, D., Memorial Sloan-Kettering Cancer Center, New York, NY, United States
dc.contributor.affiliation Maki, R.G., Memorial Sloan-Kettering Cancer Center, New York, NY, United States
dc.contributor.affiliation Keohan, M.L., Memorial Sloan-Kettering Cancer Center, New York, NY, United States
dc.contributor.affiliation Gansukh, B., Memorial Sloan-Kettering Cancer Center, New York, NY, United States
dc.contributor.affiliation Chen, H., National Cancer Institute Cancer Therapy Evaluation Program, Bethesda, MD, United States
dc.contributor.affiliation Abou-Alfa, G.K., Memorial Sloan-Kettering Cancer Center, New York, NY, United States
dc.contributor.authorAddress Daher, M.; American University of Beirut, Beirut, Lebanon
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Daher, M
dc.contributor.authorInitials Lacouture, ME
dc.contributor.authorInitials Rathkopf, D
dc.contributor.authorInitials Maki, RG
dc.contributor.authorInitials Keohan, ML
dc.contributor.authorInitials Gansukh, B
dc.contributor.authorInitials Chen, H
dc.contributor.authorInitials Abou-Alfa, GK
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Daher, M (reprint author), Amer Univ Beirut, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Blakytny Robert, 2000, Journal of Pathology, V190, P589, DOI 10.1002-(SICI)1096-9896(200004)190:5589::AID-PATH5533.0.CO;2-T; Bohula EA, 2003, ANTI-CANCER DRUG, V14, P669, DOI 10.1097-01.cad.0000092782.37568.04; Campistol JM, 2010, CLIN TRANSPLANT, V24, P149, DOI 10.1111-j.1399-0012.2010.01232.x; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038-onc.2009.172; Hyde C, 2004, J INVEST DERMATOL, V122, P1198, DOI 10.1111-j.0022-202X.2004.022527.x; KUMAR G, 2007, ANN EMERG MED, V49, P250; Kumar G, 2007, ANN EMERG MED, V49, P243, DOI 10.1016-j.annemergmed.2006.05.005; Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677-erc.1.01280; Rothenbuhler A, 2010, J CLIN ENDOCR METAB, V95, P2827, DOI 10.1210-jc.2009-2531; Rowinsky E. K., 2007, CLIN CANCER RES, V13, P5549; Sadagurski M, 2006, MOL CELL BIOL, V26, P2675, DOI 10.1128-MCB.26.7.2675-2687.2006; Soliman AT, 2001, METABOLISM, V50, P905, DOI 10.1053-meta.2001.24924; Stachelscheid H, 2008, EMBO J, V27, P2091, DOI 10.1038-emboj.2008.141; STONE OJ, 1985, DERMATOL CLIN, V3, P485; Takahashi T, 2010, INT J HEMATOL, V91, P161, DOI 10.1007-s12185-010-0505-0; Tao Y, 2007, NAT CLIN PRACT ONCOL, V4, P591, DOI 10.1038-ncponc0934; Tavakkol A, 1999, ARCH DERMATOL RES, V291, P643, DOI 10.1007-s004030050469; Wang Yan, 2007, V172, P59
dc.description.citedCount 2
dc.description.citedTotWOSCount 2
dc.description.citedWOSCount 2
dc.format.extentCount 3
dc.identifier.articleNo
dc.identifier.coden JCOND
dc.identifier.pubmedID 21606420
dc.identifier.scopusID 79960706492
dc.identifier.url
dc.publisher.address 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr J. Clin. Oncol.
dc.relation.ispartOfIssue 21
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Journal of Clinical Oncology
dc.relation.ispartofPubTitleAbbr J. Clin. Oncol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 29
dc.source.ID WOS:000292819700008
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS brivanib, 649735-46-6
dc.subject.otherChemCAS cixutumumab, 947687-12-9
dc.subject.otherChemCAS doxycycline, 10592-13-9, 17086-28-1, 564-25-0
dc.subject.otherChemCAS temsirolimus, 162635-04-3, 343261-52-9
dc.subject.otherChemCAS Antibodies, Monoclonal
dc.subject.otherChemCAS Antineoplastic Agents
dc.subject.otherChemCAS Receptor, IGF Type 1, 2.7.10.1
dc.subject.otherIndex brivanib
dc.subject.otherIndex cixutumumab
dc.subject.otherIndex doxycycline
dc.subject.otherIndex placebo
dc.subject.otherIndex somatomedin C receptor
dc.subject.otherIndex steroid
dc.subject.otherIndex temsirolimus
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex article
dc.subject.otherIndex bone metastasis
dc.subject.otherIndex brain metastasis
dc.subject.otherIndex cancer combination chemotherapy
dc.subject.otherIndex cancer radiotherapy
dc.subject.otherIndex cancer relapse
dc.subject.otherIndex case report
dc.subject.otherIndex chondrosarcoma
dc.subject.otherIndex drug induced disease
dc.subject.otherIndex drug tolerability
dc.subject.otherIndex dry skin
dc.subject.otherIndex female
dc.subject.otherIndex folliculitis
dc.subject.otherIndex hair loss
dc.subject.otherIndex human
dc.subject.otherIndex iron therapy
dc.subject.otherIndex koilonychia
dc.subject.otherIndex liver cell carcinoma
dc.subject.otherIndex lung metastasis
dc.subject.otherIndex male
dc.subject.otherIndex nail disease
dc.subject.otherIndex nail dyschromia
dc.subject.otherIndex paronychia
dc.subject.otherIndex priority journal
dc.subject.otherIndex prostate adenocarcinoma
dc.subject.otherIndex pruritus
dc.subject.otherIndex skin disease
dc.subject.otherIndex xerosis
dc.subject.otherIndex Aged
dc.subject.otherIndex Antibodies, Monoclonal
dc.subject.otherIndex Antineoplastic Agents
dc.subject.otherIndex Exanthema
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Nail Diseases
dc.subject.otherIndex Pruritus
dc.subject.otherIndex Receptor, IGF Type 1
dc.subject.otherIndex Skin Diseases
dc.subject.otherIndex Thumb
dc.subject.otherKeywordPlus IRON-DEFICIENCY ANEMIA
dc.subject.otherKeywordPlus FACTOR-I RECEPTOR
dc.subject.otherKeywordPlus PYCNODYSOSTOSIS
dc.subject.otherKeywordPlus KOILONYCHIA
dc.subject.otherKeywordPlus HORMONE
dc.subject.otherKeywordPlus DISEASE
dc.subject.otherKeywordPlus CANCER
dc.subject.otherKeywordPlus SKIN
dc.subject.otherKeywordPlus IGF
dc.subject.otherWOS Oncology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account